Morningstar

Morningstar, Inc.

Equity Bottom-Up

We're maintaining our $354 fair value estimate for Regeneron following first-quarter results. Growth for the firm's key value drivers, ocular disease drug Eylea and immunology drug Dupixent, was in line with our expectations, and Dupixent's recent approval in Europe in asthma and upcoming likely approval in the U.S. for patients with nasal polyps continue to support our bullish view on the drug. However, profits from Dupixent weren't enough to make the antibody collaboration with Sanofi…

United States

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00